A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Elranatamab
Related studies linked through entity extraction aliases.
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
- Status
- RECRUITING
- Phase
- PHASE2
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Status
- RECRUITING
- Phase
- PHASE1
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- Status
- RECRUITING
- Phase
- PHASE3
The Norwegian Immunotherapy in Multiple Myeloma Study
- Status
- RECRUITING
- Phase
- N/A
ELISA in Relapsed/Refractory MM
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Elranatamab in Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
- Status
- COMPLETED
- Phase
- N/A
Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
- Status
- COMPLETED
- Phase
- N/A
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- Status
- RECRUITING
- Phase
- PHASE1